Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bulleyaconitine A

A technology of clathrin and a drug, applied in the field of medicine, can solve the problems of easy formation of drug resistance and dependence, expensive biological preparations, etc., and achieve the effects of improving physiological indicators, reducing the area of ​​rash and relieving itching

Active Publication Date: 2020-02-04
YUNNAN HAOPY PHARM LTD
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs can play a certain therapeutic role clinically, but after long-term use, drug resistance and dependence are easy to form, and biological agents are expensive, which brings huge economic burden to patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bulleyaconitine A
  • Application of bulleyaconitine A
  • Application of bulleyaconitine A

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Embodiment 1: mouse model test

[0017] 1. Experimental animals

[0018] SPF grade BALB / C mice, body weight: 20±2g, age: 6-8 weeks, provided by the Experimental Animal Center of Kunming Medical University, male, free to eat, temperature 25±3°C, kept in SPF grade animal room.

[0019] 2. Grouping of animals

[0020] 60 BALB / C mice were randomly divided into 6 groups, including normal group, model group, experimental group A, experimental group B, and experimental group C, with 12 mice in each group.

[0021] 3. Establishment of mouse psoriasis model

[0022] Use electric clippers to shave the back hair of each mouse, and then apply a depilatory cream to remove the remaining hair on the back of the mouse, exposing the skin with an area of ​​about 3cm×2cm. Two days later, 62.5 mg of 5% imiquimod ointment was applied to the back skin of each mouse every day for 7 consecutive days. Obvious erythema, scales and thickening appeared on the back skin of the mouse, which mean...

Embodiment 2

[0062] Embodiment 2: clinical trial

[0063] 1. Research object

[0064] The observed cases came from patients who were diagnosed with psoriasis vulgaris at the Dermatology Clinic of Yunnan Provincial Hospital of Traditional Chinese Medicine from December 2017 to May 2019.

[0065] 2. Diagnostic criteria

[0066] Formulated according to "Chinese Clinical Dermatology". The skin lesions are red papules and macules, which can be fused into sheets with obvious edges and covered with multiple layers of silvery white scales. After the scales are scraped off, a layer of translucent film can be seen, and punctiform bleeding can be seen after the thin scales are removed.

[0067] 2.1 Grading criteria for disease severity

[0068] The severity of psoriasis is graded according to the area of ​​the lesion:

[0069] Mild: skin lesion area < 10% of body surface area;

[0070] Moderate disease: the area of ​​skin lesions is 10% to 30% of the body surface area;

[0071] Severe cases: sk...

Embodiment 3

[0185] Embodiment 3: Aconitin safety test

[0186] Under the GLP experimental conditions of the Chongqing Institute of Traditional Chinese Medicine (Chongqing Drug Safety Evaluation Center), the SD rats were gavaged with Aconitin Tablets for 3 months. The multiple administration toxicity test data showed that the no toxic reaction dose of Aconitin ( NOAEL) is 0.15mg / kg, the safe dose is 0.3mg / kg, and the adult and rat dose conversion is about 6.15 times different, then the adult NOAEL (NOAEL) is 0.024mg / kg, and the adult safe dose is 0.049mg / kg; if an adult is calculated as 60kg, the NOAEL for adults is 1.44mg / 60kg, and the safe dose for adults is 2.94mg / 60kg. The specific test is as follows:

[0187] Experimental observation indicators: During the experiment, observe the general conditions of the animals, such as appearance signs, behavioral activities, food intake, drinking water, urine, and feces, etc.; weigh the body weight and food intake once a week; detect hematology ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, and discloses application of bulleyaconitine A. According to the application of the bulleyaconitine A, through an animal model test and a clinical test, it is verified that the bulleyaconitine A can effectively reduce thicknesses of skin lesions, make color of the skin lesions pale, reduce an area of skin rash, relieve pruritus and improvevarious physiological indexes, relevant results are all statistically different, the curative effect of the bulleyaconitine A in treatment of psoriasis is obvious, the safety is high, and therefore,the invention provides related application of the bulleyaconitine A in the treatment of the psoriasis.

Description

technical field [0001] The invention relates to the technical field of medicine, and more specifically relates to the application of aconitin. Background technique [0002] Psoriasis (Psoriasis), also known as psoriasis, is one of the most common chronic inflammatory skin diseases. Its condition is stubborn, easy to relapse, and can cause systemic damage. Parakeratosis, inflammatory cell infiltration and angiogenesis in dermal tissue. At the same time, psoriasis can easily lead to various complications such as psoriatic arthritis, metabolic syndrome, and malignant tumors, which will bring secondary harm to patients and seriously affect the quality of life of patients and even their survival cycle. However, the exact pathogenesis of psoriasis is still unclear. Studies have shown that the occurrence of psoriasis is related to a variety of factors, including genetics, immunity, and environmental influences, among which immune mediation is the generally recognized pathogenesis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/439A61P17/06A61P17/04
CPCA61K31/439A61P17/06A61P17/04
Inventor 吴琼粉王良焜黄照昌李彪李俊生施如姣
Owner YUNNAN HAOPY PHARM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com